FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626802009> ?p ?o ?g. }

• W2626802009 endingPage "4495" @default.
• W2626802009 startingPage "4495" @default.
• W2626802009 abstract "Abstract Background: Multiple myeloma (MM) is a plasma cell malignancy characterized by mass growth of clonal plasma cells in the bone marrow, the secretion of abnormal monoclonal immunoglobulins and lytic bone lesions. Although current therapies have improved the outcome of patients, MM remains an incurable disease with a high rate of relapse and refractory. The survival of MM patients ranged from less than one month to more than 10 years. MM cells survival are more dependent on bone marrow microenvironment which induced drug-resistance of anti-MM agents. Cytogenetic aberrations of MM cell, such as chromosomal translocation, deletion and amplification induced oncogenes activation and tumor suppressor genes inactivation. Furthermore, epigenetic changes, such as histone methylation, have been suggested as a mediation of chemotherapy resistance in several cancer types, including MM. PcG (Polycomb group) proteins are conserved transcriptional repressors and essential to regulate cell fate.There were two main families of chromatin-modifying complexes, PRC1 (Polycomb repressive complex 1) and PRC2-4. In Drosophila, PRC2 contains the H3K27 histone methytransferase E (Z) whose trimethylation activity towards PcG target genes is stimulated by PCL (polycomb-like) protein. Three PCL paralogues have been identified: PHF1, MTF2 and PHF19. In this study, we found out that PHF19 is overexpressed and was related with relapse and drug resistance in multiple myeloma. Materials and methods: Gene Expression Profile Assay (GEP) was conducted in sequential patient samples including newly diagnosed, post-treatment and relapsed. 51 newly diagnosed and relapsed paired samples, 19 newly diagnosed and post-treatment paired specimens, 9 patients have newly diagnosed, post-treatment and relapsed samples at different time points were elucidated in this study. MM relapsed and drug-resistance highly correlated genes were screened and the prognosis and survival analysis were conducted. Real time quantitative PCR (RQ-PCR) and Western blotting were used to analysis the expression of the gene in MM cell lines and MM patients. The candidate gene was overexpressed in MM cells by lentiviral infection. The cell proliferation and drug sensitivity of MM cells and proteins in correlated signaling pathways were detected. Results: GEP assay showed that 56 genes expression in MM resistant clones after treatment and relapse have significantly increased, with 20 genes closely associated with the poor prognosis. Among them, PHF19, a component of the Polycomb repressive complex 2 (PRC2) family,significantly increased in relapsed and refactory patients and myeloma cell lines.The progression-free survival (PFS) and overall survival (OS) were significantly shortened in MM patients with overexpressed PHF19. PHF19 overexpression (OE) promoted the proliferation and inhibited apoptosis of MM cells. The sensitivity to doxorubicin and vincristine was significantly reduced in the PHF19 OE cells. Western blotting showed that the phosphorylation of EZH2 was significantly increased in PHF19 OE cells, while H3K27me3 level was significantly down-regulated. Overexpressed PHF19 through activating NF-κB signaling pathway induced persistent expression of EZH2 and their downstream anti-apoptotic gene, such as IGF1, BCL2 and HIF1α, which induced cell proliferation and drug resistance. Thus targeting PHF19, inhibiting the phosphorylation of EZH2 and sustaining histone H3K27 methylation level may be a potential therapeutic target in relapsed or refractory myeloma patients. Conclusion s: PHF19 expression was obviously increased in MM relapse and drug resistance patients with poor prognosis. Inhibition PHF19 and counteraction EZH2 phosphorylation should be combined to improve chemotherapy induced hypermethylation of H3K27, which may be a new therapeutic strategies in relapsed or refractory myeloma. Disclosures No relevant conflicts of interest to declare." @default.
• W2626802009 created "2017-06-23" @default.
• W2626802009 creator A5006292484 @default.
• W2626802009 creator A5009244884 @default.
• W2626802009 creator A5044751148 @default.
• W2626802009 creator A5050451872 @default.
• W2626802009 creator A5085394476 @default.
• W2626802009 date "2016-12-02" @default.
• W2626802009 modified "2023-09-28" @default.
• W2626802009 title "PHF19 Promotes Drug Resistance through EZH2 Inactivation in Multiple Myeloma" @default.
• W2626802009 doi "https://doi.org/10.1182/blood.v128.22.4495.4495" @default.
• W2626802009 hasPublicationYear "2016" @default.
• W2626802009 type Work @default.
• W2626802009 sameAs 2626802009 @default.
• W2626802009 citedByCount "1" @default.
• W2626802009 countsByYear W26268020092017 @default.
• W2626802009 crossrefType "journal-article" @default.
• W2626802009 hasAuthorship W2626802009A5006292484 @default.
• W2626802009 hasAuthorship W2626802009A5009244884 @default.
• W2626802009 hasAuthorship W2626802009A5044751148 @default.
• W2626802009 hasAuthorship W2626802009A5050451872 @default.
• W2626802009 hasAuthorship W2626802009A5085394476 @default.
• W2626802009 hasConcept C104317684 @default.
• W2626802009 hasConcept C153911025 @default.
• W2626802009 hasConcept C203014093 @default.
• W2626802009 hasConcept C2776364478 @default.
• W2626802009 hasConcept C2776396001 @default.
• W2626802009 hasConcept C2776915012 @default.
• W2626802009 hasConcept C2777478702 @default.
• W2626802009 hasConcept C2780007613 @default.
• W2626802009 hasConcept C41091548 @default.
• W2626802009 hasConcept C50171091 @default.
• W2626802009 hasConcept C502942594 @default.
• W2626802009 hasConcept C54355233 @default.
• W2626802009 hasConcept C64927066 @default.
• W2626802009 hasConcept C86803240 @default.
• W2626802009 hasConceptScore W2626802009C104317684 @default.
• W2626802009 hasConceptScore W2626802009C153911025 @default.
• W2626802009 hasConceptScore W2626802009C203014093 @default.
• W2626802009 hasConceptScore W2626802009C2776364478 @default.
• W2626802009 hasConceptScore W2626802009C2776396001 @default.
• W2626802009 hasConceptScore W2626802009C2776915012 @default.
• W2626802009 hasConceptScore W2626802009C2777478702 @default.
• W2626802009 hasConceptScore W2626802009C2780007613 @default.
• W2626802009 hasConceptScore W2626802009C41091548 @default.
• W2626802009 hasConceptScore W2626802009C50171091 @default.
• W2626802009 hasConceptScore W2626802009C502942594 @default.
• W2626802009 hasConceptScore W2626802009C54355233 @default.
• W2626802009 hasConceptScore W2626802009C64927066 @default.
• W2626802009 hasConceptScore W2626802009C86803240 @default.
• W2626802009 hasIssue "22" @default.
• W2626802009 hasLocation W26268020091 @default.
• W2626802009 hasOpenAccess W2626802009 @default.
• W2626802009 hasPrimaryLocation W26268020091 @default.
• W2626802009 hasRelatedWork W1984437179 @default.
• W2626802009 hasRelatedWork W2013220243 @default.
• W2626802009 hasRelatedWork W2024618631 @default.
• W2626802009 hasRelatedWork W2068122261 @default.
• W2626802009 hasRelatedWork W2613437790 @default.
• W2626802009 hasRelatedWork W2779058198 @default.
• W2626802009 hasRelatedWork W3045776804 @default.
• W2626802009 hasRelatedWork W3205814058 @default.
• W2626802009 hasRelatedWork W4281396028 @default.
• W2626802009 hasRelatedWork W4367173850 @default.
• W2626802009 hasVolume "128" @default.
• W2626802009 isParatext "false" @default.
• W2626802009 isRetracted "false" @default.
• W2626802009 magId "2626802009" @default.
• W2626802009 workType "article" @default.